Use of FDA Expedited Programs and Development Timelines for New Molecular Entity Drug and New Biologic Approvals by Sponsor Experience

Documenti analoghi

• Analysis of Real‐World Data Utilization in the Orphan Drug Approval Process: Focusing on New Drug Marketing Applications Submitted to the FDA
  di: Minji Kim, et al.
  Pubblicazione: (2026)
• Dose Determinations at Drug Approval Reviews: FDA‐Approved Drugs in Past 5 Years
  di: Sachiko Mita, et al.
  Pubblicazione: (2025)
• Real‐World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020–2022
  di: Gabriel K. Innes, et al.
  Pubblicazione: (2025)
• Clinical Benefit, Trials, and Regulatory Approval of Oncology Indications Under Multiple Expedited Programs for Drug Marketing in China, 2018–2024
  di: Jie Zhang, et al.
  Pubblicazione: (2025)
• Confirmatory Evidence Used in Non‐Oncologic Rare Disease New Molecular Entity Marketing Applications Approved by FDA, 2020–2023
  di: Bridget M. Nugent, et al.
  Pubblicazione: (2025)